Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Meta Expands AI Training With Employee Activity Tracking Tools 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
GAITHERSBURG, Md., March 01, 2016 -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that Bill Enright, Chief Executive Officer, will be presenting at the following conferences:
- 23rd Annual Future Leaders in the Biotech Industry Conference in New York, NY on Friday, March 11, 2016 at 2:00 PM ET
- 28th Annual ROTH Conference in Orange County, CA on Tuesday, March 15, 2016 at 2:20 PM PT
About Altimmune
Altimmune is a clinical stage immunotherapeutic company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines. Using these technologies, Altimmune has developed three novel clinical stage product candidates that potentially represent an entirely new approach to harnessing the immune system.
The Company’s most advanced product candidate, NasoVAX, is a Phase 2-ready intranasally-delivered recombinant influenza vaccine offering broad and rapid protection with potential for significant advantages over traditional flu vaccines. The second most advanced product candidate, HepTcell, is being tested as an immunotherapy for patients chronically infected with hepatitis B and has the potential to provide a functional cure. With the support of the U.S. Biomedical Advanced Research and Development Authority, or BARDA, the Company is developing a third product candidate, NasoShield, a first-in-class anthrax vaccine designed to provide rapid, stable protection after one intranasal administration. The Company intends to leverage the RespirVec and Densigen platforms to develop additional product candidates for a variety of indications.
Contacts: Bill Enright President and CEO Phone: 240-654-1450 Email: [email protected] Investor Relations Stephanie Carrington ICR, Inc. Phone: 646-277-1282 Email: [email protected]
